

**REMARKS**

The Examiner has required restriction between two groups; Group I is to compounds in Claims 1-17, 19-22 and 26; and Group II is to the compositions of Claim 27. The "use" claims 18 and 23-25 have been withdrawn. The Examiner has also required an election of species.

Applicants elect Group 1 for further prosecution, and the species elected is the 10<sup>th</sup> compound in Claim 16, 1-(4-Nitro-phenyl)-2-oxo-5-(2-pyrrolidin-1-yl-ethyl)-2,5-dihydro-1H-pyrido[3,2-b]-indole-3-carbonitrile. This compound is also described as compound 13 in the table at p. 63 and Example A7 at p. 42. The Claims reading on this species are Claims 1-17, 19, 20, and 26.

**CONCLUSION**

Early favorable action on the merits is respectfully requested.

The Commissioner is hereby authorized to charge any deficiency or credit any overpayments necessitated by this Amendment to Deposit Account No. 10-0750/TIP0042USPCT/AGK/HJP.

Respectfully submitted,

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
Phone: (732) 524-1495  
Dated: September 9, 2008

By: /Hesna J. Pfeiffer/  
Hesna J. Pfeiffer, Reg. No. 22,640